The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...
A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.